• 1
    Wallis RM, Corbin JD, Francis SH, Ellis P. Tissue distribution of phosphodiesterase families and the effect of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile response of trabeculaecarneae and aortic rings. Am J Cardiol.1999;83:3C12C.
  • 2
    Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev.1995;75:725748.
  • 3
    Reffelmann T, Kloner RA. Therapeutic potential of phosphodiesterase5 inhibition for cardiovascular disease. Circulation.2003;108:239244.
  • 4
    Senzaki H, Smith CJ, Juang GJ, et al.Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure. FASEB J.2001;15:17181726.
  • 5
    Gresser U, Gleiter CH. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil: review of the literature. Eur J Med Res.2002;7:435446.
  • 6
    Burnett AL. Phosphodiesterase 5 mechanisms and therapeutic applications. Am J Cardiol.2005;96:29Me31M.
  • 7
    Dickstein K, Cohen-Solal A, Filippatos G, et al.ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J.2008;29:23882442.
  • 8
    Hirata K, Adji A, Vlachopoulos C, O’Rourke MF. Effect of sildenafil on cardiac performance in patients with heart failure. Am J Cardiol.2005;96:14361440.
  • 9
    Borlaug BA, Melenovsky V, Marhin T, et al.Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. Circulation.2005;112:26422649.
  • 10
    Guazzi M, Tumminello G, Di Marco F, et al.The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol.2004;44:23392348.
  • 11
    Lewis GD, Lachmann J, Camuso J, et al.Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation.2007;115:5966.
  • 12
    Lewis GD, Shah R, Shahzad K, et al.Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation.2007;116:15551562.
  • 13
    Guazzi M, Samaja M, Arena R, et al.Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol.2007;50:21362144.
  • 14
    Behling A, Rohde LE, Colombo FC, et al.Effects of 5′-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial. J Card Fail.2008;14:189197.